Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)

 
Sponsors and Collaborators
Celldex Therapeutics
 
Contact
Celldex Therapeutics
 
ClinicalTrials.gov Identifier
NCT01480479